期刊
AMERICAN JOURNAL OF KIDNEY DISEASES
卷 60, 期 6, 页码 1012-1022出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2012.08.034
关键词
Acute kidney injury; chronic kidney disease; end-stage renal disease; stem cells; protection; regeneration; trophic factors; anti-inflammatory actions
资金
- Merit Review program of the Veterans Administration
- National Institutes of Health
- American Heart Association
- National Kidney Foundation
- Dialysis Research Foundation
- Western Institute for Biomedical Research
- Allocure Inc.
- Nephrogen LLC
Acute kidney injury (AKI) is a common clinical entity with high morbidity and mortality rates and ever increasing medical costs. A large number of patients who are hospitalized with morbidities such as diabetes, vascular disease, or chronic kidney disease are at high risk to develop AKI due to ischemic and nephrotoxic insults. The pathophysiology of ischemic and toxic forms of AKI is complex and includes tubular and vascular cell damage and inflammation. Given the seriousness of this essentially therapy-resistant complication, treatment beyond supportive measures and renal replacement therapy is urgently needed. Recent stem cell research has shown promising results, and cell therapy-based interventions are advancing into clinical trials. An example is our phase 1 clinical trial (NCT00733876) in which cardiac surgery patients at high risk of postoperative AKI were treated safely with allogeneic mesenchymal stem cells. Together with the introduction of biomarkers for an earlier and specific AKI diagnosis, currently tested stem cell-based therapies are expected to provide an entirely new class of diagnostic and therapeutic tools. Am J Kidney Dis. 60(6): 1012-1022. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据